Cargando…

HSP47: A Therapeutic Target in Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by a progressive decline in lung function and poor prognosis. The deposition of the extracellular matrix (ECM) by myofibroblasts contributes to the stiffening of lung tissue and impaired oxygen exchange in IPF. Type I collag...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakamoto, Noriho, Okuno, Daisuke, Tokito, Takatomo, Yura, Hirokazu, Kido, Takashi, Ishimoto, Hiroshi, Tanaka, Yoshimasa, Mukae, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525413/
https://www.ncbi.nlm.nih.gov/pubmed/37760828
http://dx.doi.org/10.3390/biomedicines11092387
_version_ 1785110778133610496
author Sakamoto, Noriho
Okuno, Daisuke
Tokito, Takatomo
Yura, Hirokazu
Kido, Takashi
Ishimoto, Hiroshi
Tanaka, Yoshimasa
Mukae, Hiroshi
author_facet Sakamoto, Noriho
Okuno, Daisuke
Tokito, Takatomo
Yura, Hirokazu
Kido, Takashi
Ishimoto, Hiroshi
Tanaka, Yoshimasa
Mukae, Hiroshi
author_sort Sakamoto, Noriho
collection PubMed
description Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by a progressive decline in lung function and poor prognosis. The deposition of the extracellular matrix (ECM) by myofibroblasts contributes to the stiffening of lung tissue and impaired oxygen exchange in IPF. Type I collagen is the major ECM component and predominant collagen protein deposited in chronic fibrosis, suggesting that type I collagen could be a target of drugs for fibrosis treatment. Heat shock protein 47 (HSP47), encoded by the serpin peptidase inhibitor clade H, member 1 gene, is a stress-inducible collagen-binding protein. It is an endoplasmic reticulum-resident molecular chaperone essential for the correct folding of procollagen. HSP47 expression is increased in cellular and animal models of pulmonary fibrosis and correlates with pathological manifestations in human interstitial lung diseases. Various factors affect HSP47 expression directly or indirectly in pulmonary fibrosis models. Overall, understanding the relationship between HSP47 expression and pulmonary fibrosis may contribute to the development of novel therapeutic strategies.
format Online
Article
Text
id pubmed-10525413
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105254132023-09-28 HSP47: A Therapeutic Target in Pulmonary Fibrosis Sakamoto, Noriho Okuno, Daisuke Tokito, Takatomo Yura, Hirokazu Kido, Takashi Ishimoto, Hiroshi Tanaka, Yoshimasa Mukae, Hiroshi Biomedicines Review Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by a progressive decline in lung function and poor prognosis. The deposition of the extracellular matrix (ECM) by myofibroblasts contributes to the stiffening of lung tissue and impaired oxygen exchange in IPF. Type I collagen is the major ECM component and predominant collagen protein deposited in chronic fibrosis, suggesting that type I collagen could be a target of drugs for fibrosis treatment. Heat shock protein 47 (HSP47), encoded by the serpin peptidase inhibitor clade H, member 1 gene, is a stress-inducible collagen-binding protein. It is an endoplasmic reticulum-resident molecular chaperone essential for the correct folding of procollagen. HSP47 expression is increased in cellular and animal models of pulmonary fibrosis and correlates with pathological manifestations in human interstitial lung diseases. Various factors affect HSP47 expression directly or indirectly in pulmonary fibrosis models. Overall, understanding the relationship between HSP47 expression and pulmonary fibrosis may contribute to the development of novel therapeutic strategies. MDPI 2023-08-25 /pmc/articles/PMC10525413/ /pubmed/37760828 http://dx.doi.org/10.3390/biomedicines11092387 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sakamoto, Noriho
Okuno, Daisuke
Tokito, Takatomo
Yura, Hirokazu
Kido, Takashi
Ishimoto, Hiroshi
Tanaka, Yoshimasa
Mukae, Hiroshi
HSP47: A Therapeutic Target in Pulmonary Fibrosis
title HSP47: A Therapeutic Target in Pulmonary Fibrosis
title_full HSP47: A Therapeutic Target in Pulmonary Fibrosis
title_fullStr HSP47: A Therapeutic Target in Pulmonary Fibrosis
title_full_unstemmed HSP47: A Therapeutic Target in Pulmonary Fibrosis
title_short HSP47: A Therapeutic Target in Pulmonary Fibrosis
title_sort hsp47: a therapeutic target in pulmonary fibrosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525413/
https://www.ncbi.nlm.nih.gov/pubmed/37760828
http://dx.doi.org/10.3390/biomedicines11092387
work_keys_str_mv AT sakamotonoriho hsp47atherapeutictargetinpulmonaryfibrosis
AT okunodaisuke hsp47atherapeutictargetinpulmonaryfibrosis
AT tokitotakatomo hsp47atherapeutictargetinpulmonaryfibrosis
AT yurahirokazu hsp47atherapeutictargetinpulmonaryfibrosis
AT kidotakashi hsp47atherapeutictargetinpulmonaryfibrosis
AT ishimotohiroshi hsp47atherapeutictargetinpulmonaryfibrosis
AT tanakayoshimasa hsp47atherapeutictargetinpulmonaryfibrosis
AT mukaehiroshi hsp47atherapeutictargetinpulmonaryfibrosis